By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission? - 2Sustaining Public activity and Connections: Key Methodologies
- 3Pentagon advances Golden Dome missile defense with new Space Force contracts
- 4The Rhythms of the Street: Shipping's Tune in the Economy's Symphony
- 5A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu
- Doctored NXT Summit footage falsely portrays Modi as declaring war on Iran and Pakistan
- Five held on suspicion of planning attack on German Christmas market
- Flying without a Real ID? That'll soon cost you $45, TSA says.
- 75% of US adults may meet criteria for obesity under new definition, study finds
- The Following Huge Thing: 5 Progressive Tech New businesses
- ‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
